11 results
The primary efficacy variable is the change in PV from baseline as assessed by 3 D ultrasonography after 78 weeks of double-blind treatment with OM 20-40 mg daily compared to ATE 50-100 mg daily.Secondary efficacy variables:Change from baseline PV…
Main objective: * To evaluate the effect and variation of 3 and 12 months treatment with Aliskeren-based versus amlodipine-based antihypertensive treatment on aneurismal FDG- uptakeExploratory objectives: * To explore the effect of 3 and 12 months…
Determinination of the added effects of dietary sodium restriction or diuretic use to antihypertensive and antialbuminuric therapy.
Primary objective: to compare changes in endothelial function in patients with obesity related hypertension after 8 weeks of treatment with aliskiren, moxonidine and HCTZ.Secondary objectives: to compare changes in the following parameters in…
Primary: Period II (Week 8 to Week 16)1. To demonstrate the additional antihypertensive efficacy for seated diastolic blood pressure (SeDBP) gained by adding HCTZ 12.5 or 25 mg to the treatment regimen in subjects with moderate to severe HTN not…
Primary objective: To assess the safety and efficacy of endovascular renal nerve ablation using the Boston Scientific Vessix V2 renal denervation system in patients with systolic heart failure
The aim of this study is to evaluate cardio-protective effects of xenon inhalation in humans and to identify enzymes contributing to cardio-protection influenced by xenon in patients scheduled for CABG surgery.
The aim of this study is to evaluate the immediate effect of xenon inhalation on cardiac performance in patients scheduled for CABG surgery in comparison with the effect induced by sevoflurane inhalation.
To compare the effect of amiloride on lithium-induced Nephrogenic Diabetes Insipidus with the effect of hydrochlorothiazide, measured as urine volume and maximal urine osmolality.
To demonstrate whether hydrochlorothiazide or metformin can diminish aquaresis in patients with ADPKD who are treated with tolvaptan as measured by 24-hour urine volume.
To examine the impact of medication induced systolic BP (SBP) reductions >=10 mmHg, while reaching a treatment target of <=140 mmHg, on cerebral blood flow (CBF) in frail elderly with untreated or uncontrolled systolic hypertension at…